Literature DB >> 15493880

Effects of short-term chemical ablation of the GIP receptor on insulin secretion, islet morphology and glucose homeostasis in mice.

Nigel Irwin1, Victor A Gault, Brian D Green, Brett Greer, Jane T McCluskey, Patrick Harriott, Finbarr P M O'Harte, Peter R Flatt.   

Abstract

Glucose-dependent insulinotropic polypeptide (GIP) is an incretin hormone secreted by endocrine K-cells in response to nutrient absorption. In this study we have utilized a specific and enzymatically stable GIP receptor antagonist, (Pro3)GIP, to evaluate the contribution of endogenous GIP to insulin secretion and glucose homeostasis in mice. Daily injection of (Pro3)GIP (25 nmol/kg body weight) for 11 days had no effect on food intake or body weight. Non-fasting plasma glucose concentrations were significantly raised (p<0.05) by day 11, while plasma insulin concentrations were not significantly different from saline treated controls. After 11 days, intraperitoneal glucose tolerance was significantly impaired in the (Pro3)GIP treated mice compared to control (p<0.01). Glucose-mediated insulin secretion was not significantly different between the two groups. Insulin sensitivity of 11-day (Pro3)GIP treated mice was slightly impaired 60 min post injection compared with controls. Following a 15 min refeeding period in 18 h fasted mice, food intake was not significantly different in (Pro3)GIP treated mice and controls. However, (Pro3)GIP treated mice displayed significantly elevated plasma glucose levels 30 and 60 min post feeding (p<0.05, in both cases). Postprandial insulin secretion was not significantly different and no changes in pancreatic insulin content or islet morphology were observed in (Pro3)GIP treated mice. The observed biological effects of (Pro3)GIP were reversed following cessation of treatment for 9 days. These data indicate that ablation of GIP signaling causes a readily reversible glucose intolerance without appreciable change of insulin secretion.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15493880     DOI: 10.1515/BC.2004.110

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  12 in total

Review 1.  Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins.

Authors:  Marzieh Salehi; Benedikt A Aulinger; David A D'Alessio
Journal:  Endocr Rev       Date:  2008-02-21       Impact factor: 19.871

2.  Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro3)GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice.

Authors:  N Irwin; P L McClean; F P M O'Harte; V A Gault; P Harriott; P R Flatt
Journal:  Diabetologia       Date:  2007-05-08       Impact factor: 10.122

Review 3.  Obesity medications in development.

Authors:  Candida J Rebello; Frank L Greenway
Journal:  Expert Opin Investig Drugs       Date:  2019-12-19       Impact factor: 6.206

4.  Short-term and mid-term control of type 2 diabetes mellitus by laparoscopic sleeve gastrectomy with ileal interposition.

Authors:  Augusto Tinoco; Luciana El-Kadre; Livia Aquiar; Renam Tinoco; Paulo Savassi-Rocha
Journal:  World J Surg       Date:  2011-10       Impact factor: 3.352

5.  Emetic Response to T-2 Toxin Correspond to Secretion of Glucagon-like Peptide-17-36 Amide and Glucose-Dependent Insulinotropic Polypeptide.

Authors:  Jie Zhang; Tushuai Li; Qinghua Wu; Zihui Qin; Ben Wei; Ran Wu; Xinyi Guo; Huiping Xiao; Wenda Wu
Journal:  Toxins (Basel)       Date:  2022-06-02       Impact factor: 5.075

Review 6.  Evidence for beneficial effects of compromised gastric inhibitory polypeptide action in obesity-related diabetes and possible therapeutic implications.

Authors:  N Irwin; P R Flatt
Journal:  Diabetologia       Date:  2009-06-17       Impact factor: 10.122

7.  Hormonal evaluation following laparoscopic treatment of type 2 diabetes mellitus patients with BMI 20-34.

Authors:  Aureo Ludovico DePaula; A L V Macedo; V Schraibman; B R Mota; S Vencio
Journal:  Surg Endosc       Date:  2008-10-02       Impact factor: 4.584

8.  Prediction of remission after metabolic surgery using a novel scoring system in type 2 diabetes - a retrospective cohort study.

Authors:  Surendra Ugale; Neeraj Gupta; Kirtikumar D Modi; Sunil K Kota; Vasisht Satwalekar; Vishwas Naik; Modukuri Swapna; Kvs Hari Kumar
Journal:  J Diabetes Metab Disord       Date:  2014-08-22

9.  Ileal interposition with sleeve gastrectomy for treatment of type 2 diabetes mellitus.

Authors:  Sunil Kumar Kota; Surendra Ugale; Neeraj Gupta; Vishwas Naik; K V S Hari Kumar; Kirtikumar D Modi
Journal:  Indian J Endocrinol Metab       Date:  2012-07

10.  Vaccination against GIP for the treatment of obesity.

Authors:  Alma Fulurija; Thomas A Lutz; Katja Sladko; Melania Osto; Peter Y Wielinga; Martin F Bachmann; Philippe Saudan
Journal:  PLoS One       Date:  2008-09-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.